Rein Therapeutics, Inc. (RNTX)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenue | - | - | ||
| Research and development | 4,292 | 3,054 | ||
| General and administrative | 2,579 | 2,555 | ||
| Total operating expenses | 6,871 | 5,609 | ||
| Loss from operations | -6,871 | -5,609 | ||
| Other income, net | 49 | 108 | ||
| Net loss | -6,822 | -5,501 | ||
| Unrealized gain on investments, net of tax of 0 | 12 | -45 | ||
| Foreign currency translation adjustments | -24 | 31 | ||
| Total other comprehensive gain | -12 | -14 | ||
| Total comprehensive loss | -6,834 | -5,515 | ||
| Earnings per share, basic | -0.28 | -0.25 | ||
| Earnings per share, diluted | -0.28 | -0.25 | ||
| Weighted average common shares outstanding - basic | 24,187,536 | 21,915,891 | ||
| Weighted average common shares outstanding - diluted | 24,187,536 | 21,915,891 | ||